Westside Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $973K | Sell |
6,150
-150
| -2% | -$20.3K | 0.13% | 147 |
|
|
2026
Q1 | $805K | Buy |
6,300
+100
| +2% | +$12.5K | 0.12% | 151 |
|
|
2025
Q4 | $756K | Sell |
6,200
-150
| -2% | -$17.2K | 0.12% | 142 |
|
|
2025
Q3 | $636K | Buy |
6,350
+200
| +3% | +$18K | 0.1% | 157 |
|
|
2025
Q2 | $510K | Sell |
6,150
-20
| -0.3% | -$1.6K | 0.09% | 162 |
|
|
2025
Q1 | $500K | Hold |
6,170
| – | – | 0.11% | 153 |
|
|
2024
Q4 | $556K | Hold |
6,170
| – | – | 0.12% | 142 |
|
|
2024
Q3 | $610K | Buy |
6,170
+200
| +3% | +$19.6K | 0.13% | 142 |
|
|
2024
Q2 | $553K | Hold |
5,970
| – | – | 0.13% | 143 |
|
|
2024
Q1 | $566K | Hold |
5,970
| – | – | 0.14% | 137 |
|
|
2023
Q4 | $533K | Sell |
5,970
-1,250
| -17% | -$92.8K | 0.14% | 138 |
|
|
2023
Q3 | $527K | Sell |
7,220
-150
| -2% | -$12K | 0.15% | 134 |
|
|
2023
Q2 | $613K | Sell |
7,370
-50
| -0.7% | -$4.18K | 0.17% | 121 |
|
|
2023
Q1 | $565K | Sell |
7,420
-100
| -1% | -$8.3K | 0.17% | 121 |
|
|
2022
Q4 | $82.1K | Buy |
7,520
+1,130
| +18% | +$91.5K | 0.2% | 99 |
|
|
2022
Q3 | $506 | Hold |
6,390
| – | – | ﹤0.01% | 292 |
|
|
2022
Q2 | $474 | Hold |
6,390
| – | – | ﹤0.01% | 286 |
|
|
2022
Q1 | $574 | Hold |
6,390
| – | – | ﹤0.01% | 287 |
|
|
2021
Q4 | $715 | Buy |
6,390
+40
| +0.6% | +$4.82K | ﹤0.01% | 269 |
|
|
2021
Q3 | $798 | Buy |
6,350
+250
| +4% | +$32.2K | ﹤0.01% | 262 |
|
|
2021
Q2 | $825 | Sell |
6,100
-50
| -0.8% | -$6.57K | ﹤0.01% | 250 |
|
|
2021
Q1 | $834 | Sell |
6,150
-220
| -3% | -$32.9K | ﹤0.01% | 241 |
|
|
2020
Q4 | $896 | Sell |
6,370
-100
| -2% | -$12.8K | ﹤0.01% | 201 |
|
|
2020
Q3 | $720 | Hold |
6,470
| – | – | ﹤0.01% | 218 |
|
|
2020
Q2 | $724 | Sell |
6,470
-100
| -2% | -$9.85K | ﹤0.01% | 191 |
|
|
2020
Q1 | $508 | Buy |
+6,570
| New | +$582K | ﹤0.01% | 202 |
|
|
2019
Q2 | $628K | Buy |
+7,170
| New | +$612K | 0.23% | 86 |
|
|
2018
Q4 | $717K | Buy |
9,990
+2,320
| +30% | +$187K | 0.26% | 68 |
|
|
2018
Q3 | $709K | Hold |
7,670
| – | – | 0.23% | 69 |
|
|
2018
Q2 | $739K | Buy |
7,670
+1,460
| +24% | +$134K | 0.26% | 65 |
|
|
2018
Q1 | $521K | Buy |
6,210
+2,530
| +69% | +$231K | 0.29% | 75 |
|
|
2017
Q4 | $314K | Buy |
3,680
+3,430
| +1,372% | +$287K | 0.17% | 121 |
|
|
2017
Q3 | $21.9K | Buy |
250
+100
| +67% | +$8.02K | 0.01% | 371 |
|
|
2017
Q2 | $11.6K | Hold |
150
| – | – | 0.01% | 497 |
|
|
2017
Q1 | $10K | Buy |
+150
| New | +$10.1K | ﹤0.01% | 505 |
|
Other funds holding XBI
JFG
Westside Investment Management's XBI Position: Q2 2026 in Review
Westside Investment Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2.4% in Q2 2026, selling an estimated $20.3K and leaving 6,150 shares worth $973K. The position accounts for 0.13% of the portfolio, ranked #147.
Westside Investment Management first reported a position in XBI in Q1 2017 and has held it in 35 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Westside Investment Management held 6,150 shares of State Street SPDR S&P Biotech ETF worth $973K as of Q2 2026.
- Westside Investment Management sold 150 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $20.3K.
- State Street SPDR S&P Biotech ETF made up 0.13% of Westside Investment Management's portfolio in Q2 2026, its #147 holding.
- Westside Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 35 quarters since.
- 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Westside Investment Management's 13F filing for Q2 2026, filed 27 Jul 2026.